GREAT POINT PARTNERS LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+49,877
(35.2%)
New positions
15
Sold out positions
7
Turnover %
54.8%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ALIMERA SCIENCES INC | 11,835 | NEW |
| DERMA SCIENCES INC | 11,729 | NEW |
| OXYGEN BIOTHERAPEUTICS INC | 11,100 | NEW |
| NBIX | 9,982 | NEW |
| ORTHOFIX INTL N V | 7,538 | NEW |
| ANTHERA PHARMACEUTICALS INC | 4,587 | NEW |
| FURIEX PHARMA INC | 4,486 | 33.4% |
| Societal CDMO, Inc. | 4,246 | NEW |
| CARA THERAPEUTICS INC | 3,314 | NEW |
| CYTK | 2,993 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| AERIE PHARMACEUTICALS INC | -5,539 | -100.0% |
| SUNSHINE HEART INC | -4,647 | -52.3% |
| CYNOSURE INC - CL A | -4,529 | -100.0% |
| HEARTWARE INTERNATIONAL INC | -4,394 | -100.0% |
| ChemoCentryx, Inc. | -4,134 | -71.4% |
| Horizon Therapeutics PLC Com | -3,810 | -100.0% |
| HYPERION THERAPEUTICS INC | -3,662 | -22.3% |
| OCERA THERAPEUTICS INC | -3,566 | -52.0% |
| NANOSPHERE INC R3 | -2,972 | -51.9% |
| AVEO PHARMACEUTICALS, INC. | -1,205 | -21.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
11,638
(6.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|